{"product_id":"global-biosimilar-monoclonal-antibody-market-growth-status-and-outlook-2023-2029","title":"Global Biosimilar Monoclonal Antibody Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Biosimilar Monoclonal Antibody Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nMonoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.\u003c\/p\u003e\n\n\u003cp\u003eBiosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Biosimilar Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world Biosimilar Monoclonal Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar Monoclonal Antibody sales for 2023 through 2029. With Biosimilar Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Monoclonal Antibody industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Biosimilar Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar Monoclonal Antibody market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Monoclonal Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Monoclonal Antibody.\u003c\/p\u003e\n\n\u003cp\u003eThe global Biosimilar Monoclonal Antibody market size is projected to grow from US$ 4411.1 million in 2022 to US$ 5622.5 million in 2029; it is expected to grow at a CAGR of 3.5% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.\u003c\/p\u003e\n\n\u003cp\u003eEurope is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.\u003c\/p\u003e \n\n\u003cp\u003eIn terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibody market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nLimited Dilution Method\u003cbr\u003e\nMicromanipulation\u003cbr\u003e\nSoft Agar Plate Method\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nChronic \u0026amp; Autoimmune Diseases\u003cbr\u003e\nOncology\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nBiocon\u003cbr\u003e\nAccord Healthcare\u003cbr\u003e\nAET Biotech\u003cbr\u003e\nAmgen\u003cbr\u003e\nCelltrion\u003cbr\u003e\nReddy's Laboratories\u003cbr\u003e\nHospira\u003cbr\u003e\n3SBio\u003cbr\u003e\nAllergan\u003cbr\u003e\nAlvartis\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"February, 2023 \/ 102 Pages \/ MCW16227534","offer_id":47645971218738,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true},{"title":"February, 2023 \/ 102 Pages \/ MCW16227535","offer_id":47645971251506,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-biosimilar-monoclonal-antibody-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}